|Articles|October 1, 2014
- Applied Clinical Trials-10-01-2014
- Volume 23
- Issue 10
Applied Clinical Trials Digital Edition October/November 2014
Trial Design: Identify Blood Pressure Effects Early Demonstrating Biosimilarity CRO/Sponsor: Data Monitoring Committee Users Guide Also in this issue: EU Reshuffling Impacts Pharma "Open Integration" Promise Elusive Assessing Drug-Impaired Driving
Advertisement
Articles in this issue
almost 12 years ago
Ebola Research Requires Flexibility by Sponsors, Regulatorsalmost 12 years ago
Is 'Open Integration' Beyond Our Reach?almost 12 years ago
Cognitive Guidance for Clinical Drug Trialsalmost 12 years ago
All Change for Pharma at the European Commissionalmost 12 years ago
Europe Unveils Plan to Standardize Clinical Developmentalmost 12 years ago
Implementation and Usage of Data Monitoring Committeesalmost 12 years ago
Placement of Trials Increasingly Dispersedalmost 12 years ago
ACT coveralmost 12 years ago
Demonstrating Biosimilarity: PK Considerationsalmost 12 years ago
Blood Pressure Evaluation During Early Phase TrialsAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
3
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
4
Built-In, Not Bolted On: Why Clinical Data Security Has to Be a Design Principle
5